Paolo Tarantino: Large Meta-Analysis on HER2DX and Survival Outcomes in Early-Stage HER2-Positive Breast Cancer
Paolo Tarantino, Research Fellow at Dana-Farber Cancer Institute, shared a recent article he and his colleagues co-authored on X, adding:
“Very glad to contribute to this large (11 trials, 2500 pts) meta-analysis led by Guillermo Villacampa, now out in The Lancet Oncology.
Half of the patients had high HER2DX risk score and were found to have a significantly higher risk of recurrence, irrespective of pCR/RD.”
Title: HER2DX and survival outcomes in early-stage HER2-positive breast cancer: an individual patient-level meta-analysis
Authors: Guillermo Villacampa, Tomás Pascual, Paolo Tarantino, Javier Cortés, José Perez-García, Antonio Llombart-Cussac, Pierfranco Conte, Mario Mancino, Valentina Guarneri, Maria Vittoria Dieci, Adrienne G Waks, Francesco Schettini, Fara Brasó-Maristany, Gaia Griguolo, Beatriz Alonso de Castro, Cristina Reboredo, Silvia Antolín, Coralia Bueno-Muiño, Isabel Echavarría, Sara López-Tarruella, Sara M Tolaney
Read the Full Article on The Lancet Oncology
More posts featuring Paolo Tarantino.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023